leadf
logo-loader
viewMaxCyte Inc

MaxCyte's Doug Doerfler 'confident of providing long-term treatment' for CGD patients

Doug Doerfler, president and chief executive of MaxCyte, Inc. (LON:MXCT) tells Proactive they're to continue their collaboration with one of the world’s leading infectious disease institutes after signing a cooperative research and development agreement with the US National Institute of Allergy and Infectious Diseases (NIAD).

The two will work together to explore the development of new therapies for X-linked chronic granulomatous disease (CGD) using MaxCyte’s Flow Electroporation gene-correction platform.

Quick facts: MaxCyte Inc

Price: 335 GBX

AIM:MXCT
Market: AIM
Market Cap: £258.49 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

MaxCyte Inc: Analyst talks expansion of its phase I clinical trial of MCY-M11

Proactive Research analyst Emma Ulker discusses the update this morning from MaxCyte Inc (LON:MXCT) on the expansion of its phase I clinical trial of MCY-M11 - its differentiated lead cell therapy candidate currently in first-in-human studies for advanced solid cancers. Ulker says the move is a...

on 18/8/20

2 min read